Holen Sie sich die Stockscreener-App
44.75
6.45%
2.71
Handel nachbörslich:
43.00
-1.75
-3.91%
Schlusskurs vom Vortag:
$42.04
Offen:
$42.445
24-Stunden-Volumen:
4.56M
Relative Volume:
1.71
Marktkapitalisierung:
$9.24B
Einnahmen:
$2.10B
Nettoeinkommen (Verlust:
$402.17M
KGV:
23.12
EPS:
1.9357
Netto-Cashflow:
$403.87M
1W Leistung:
+1.29%
1M Leistung:
+1.24%
6M Leistung:
+9.07%
1J Leistung:
-3.22%
1-Tages-Spanne:
$42.18
$45.60
1-Wochen-Bereich:
$41.94
$45.60
52-Wochen-Spanne:
$32.53
$57.81
Qiagen Nv Stock (QGEN) Company Profile
Firmenname
Qiagen Nv
Sektor
Branche
Telefon
-
Adresse
-
Compare QGEN vs TMO, DHR, NTRA, A, IQV
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QGEN
Qiagen Nv
|
44.75 | 9.12B | 2.10B | 402.17M | 403.87M | 1.9357 |
TMO
Thermo Fisher Scientific Inc
|
654.80 | 241.26B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
214.06 | 150.48B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
410.35 | 59.47B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
167.78 | 48.71B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
258.21 | 44.50B | 16.63B | 1.39B | 2.12B | 8.0674 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-14 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2026-03-13 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2026-01-22 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-06-24 | Eingeleitet | Barclays | Overweight |
| 2025-04-04 | Herabstufung | Redburn Atlantic | Buy → Neutral |
| 2025-02-19 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-12-10 | Hochstufung | Jefferies | Hold → Buy |
| 2024-10-17 | Herabstufung | HSBC Securities | Buy → Hold |
| 2024-06-27 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-12-19 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-07 | Hochstufung | Goldman | Neutral → Buy |
| 2023-09-12 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-05-23 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-18 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-01-18 | Hochstufung | DZ Bank | Hold → Buy |
| 2021-10-15 | Fortgesetzt | Cowen | Market Perform |
| 2021-10-14 | Eingeleitet | Redburn | Buy |
| 2021-07-14 | Herabstufung | Kepler | Buy → Hold |
| 2021-06-03 | Eingeleitet | Goldman | Neutral |
| 2020-10-06 | Fortgesetzt | BofA Securities | Buy |
| 2020-09-28 | Hochstufung | Kepler | Hold → Buy |
| 2020-08-24 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-08-20 | Fortgesetzt | JP Morgan | Overweight |
| 2020-08-17 | Hochstufung | Berenberg | Hold → Buy |
| 2020-08-14 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2020-08-14 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2020-03-04 | Herabstufung | Berenberg | Buy → Hold |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Neutral |
| 2019-12-26 | Fortgesetzt | BofA/Merrill | Underperform |
| 2019-11-15 | Eingeleitet | Stifel | Hold |
| 2019-11-14 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-11-14 | Hochstufung | JP Morgan | Underweight → Overweight |
| 2019-11-14 | Hochstufung | Kepler | Reduce → Hold |
| 2019-10-17 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2019-10-09 | Herabstufung | Kepler | Hold → Reduce |
| 2019-10-08 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-10-08 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2019-10-08 | Herabstufung | JP Morgan | Neutral → Underweight |
Alle ansehen
Qiagen Nv Aktie (QGEN) Neueste Nachrichten
Qiagen stock after-hours at EUR 38.04: minus 1.73 percent versus prior close - AD HOC NEWS
Global Liver Cancer Diagnostics Market to Observe Impressive Growth at a CAGR of ~9% by 2034 | DelveInsight - GlobeNewswire Inc.
Qiagen launches QIAmini as Qiagen stock sits 17.73 percent below its high - AD HOC NEWS
Qiagen stock last at EUR 38.72 on September 30, 2026 - AD HOC NEWS
Qiagen stock last at EUR 38.72 on September 30, 2026, down 1.02 percent - AD HOC NEWS
Release according to Article 40, Section 1 of the WpHG - TradingView
QIAGEN N.V. (QIA): BlackRock Holds 12.97% Voting Rights - TradingView
QIAGEN N.V. (QIA) Reports AFM BlackRock Voting Rights Notice - TradingView
QIAGEN N.V. (QIA) Discloses AFM Notice on BlackRock Voting Rights - TradingView
QIAGEN N.V. (QIA) Reports AFM Voting Rights Notice - TradingView
Qiagen N.V. (QGEN) Stock Price, News, Quote & History - Yahoo! Finance Canada
QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel - BioBuzz
Qiagen stock expands its sepsis testing portfolio - AD HOC NEWS
Qiagen stock last at EUR 39.12 on September 29, 2026: minus 0.46 percent versus Xetra close - AD HOC NEWS
Qiagen NV (CEUX:QIAD) Cyclically Adjusted PB Ratio : (As of Sep. 29, 2026) - GuruFocus
Qiagen NV at Citi Global Healthcare Conference Transcript - GuruFocus
Qiagen stock last stood at EUR 39.08 as FDA tests expand - AD HOC NEWS
Preliminary Q1 2026 Qiagen NV Earnings Call Transcript - GuruFocus
Qiagen (QGEN), What Is Behind The Fresh Attention Now? - Yahoo Finance
Qiagen grounds drug discovery agents in curated knowledge - SiliconANGLE
Qiagen stock at USD 45.47 on September 28, 2026 - AD HOC NEWS
Veterinary Diagnostics Market Size to Soar to USD 30.78 Billion by 2035 at a CAGR of 10.1% - GlobeNewswire Inc.
Qiagen stock gets a fresh FDA catalyst from QIAstat-Dx - AD HOC NEWS
QIAGEN says FDA cleared second QIAstat‑Dx bloodstream panel - Mugglehead Investment Magazine
A new infection test finds 13 bacteria and 18 signs of antibiotic resistance in about an hour. - Stock Titan
Qiagen N.V. (NYSE:QGEN) Stock Has Consensus Target Price of $43.51 - MarketBeat
Qiagen stock last at EUR 39.470, up 1.64 percent in Xetra trading - AD HOC NEWS
Warren Wise decodes Qiagen’s DNA - TradingView
Qiagen stock gains 1.94 percent with Q2 results above estimates - AD HOC NEWS
Qiagen launches QIAmini to automate small-batch sample preparation - BioSpectrum Asia
Qiagen N.V. $QGEN Holdings Raised by State Street Corp - MarketBeat
Qiagen stock gains 1.43 percent ahead of the open - AD HOC NEWS
Qiagen launches compact automated sample prep system - Investing.com
Qiagen launches compact automated sample prep system By Investing.com - Investing.com Nigeria
QIAGEN Launches QIAmini to Automate Small-Batch Sample Preparation - marketscreener.com
Qiagen launches compact QIAmini sample prep system for small labs - StreetInsider
Here's Why You Should Hold QIAGEN Stock in Your Portfolio for Now - Yahoo Finance
Qiagen N.V. : Deutsche Bank remains its Buy rating - marketscreener.com
QIAGEN (NYSE:QGEN) Eyes Breakout With Technical Rating 7 and Setup Rating 9 - ChartMill
Qiagen stock heads into the open after a 3.4 percent gain - AD HOC NEWS
Qiagen stock was last quoted at USD 44.78 after the close - AD HOC NEWS
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView
QIAGEN N.V. (QIA) Receives AFM Notice on BlackRock Voting Rights - TradingView
QIAGEN N.V. (QIA) Notified of Millennium 2.99% Stake - TradingView
QIAGEN N.V. (QIA) AFM Posts Voting Rights Notice - TradingView
QIAGEN N.V. (QIA) Discloses Goldman Sachs 3.41% Voting Rights - TradingView
QIAGEN N.V. (QIA) Notes AFM Voting Rights Filing by Goldman Sachs - TradingView
QIAGEN N.V. (QIA) Notes AFM Voting Rights Notification - TradingView
QIAGEN N.V. (QIA) Reports AFM Notice of BlackRock Voting Rights - TradingView
QIAGEN N.V. (QIA) Notes AFM Filing on BlackRock Voting Rights - TradingView
Qiagen stock holds at USD 44.78 below its yearly high - AD HOC NEWS
Finanzdaten der Qiagen Nv-Aktie (QGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.97%
0.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):